Living With Breast Cancer
Living With Breast Cancer
November 2004 (Newstream) --
ANCHOR LEAD: A woman's chance of remaining cancer-free following successful treatment for five years with tamoxifen for early breast cancer just got better, thanks to the approval of a new therapy for postmenopausal women. Matt Kelly has more. (:60)
SCRIPT: Healthcare Now, I'm Matt Kelly. Pharmaceutical giant Novartis has just announced a major milestone in the treatment of breast cancer. The drug manufacturer just received FDA approval for Femara in the extended adjuvant setting, making it the first and only post-tamoxifen treatment for postmenopausal women diagnosed with early breast cancer. Dr. Paul Goss, Professor Harvard Medical School.
CUT: (Goss) "The FDA's approval of Femara in the extended adjuvant setting is great news for breast cancer patients because, for the first time, it offers them a new treatment option to help improve their chances of remaining cancer-free after their standard five years of post-surgery tamoxifen therapy."
SCRIPT: An oral once-a-day therapy, Femara plays an important role in suppressing estrogen production, which can cause certain breast cancer cells to grow. To find out more about treatments for breast cancer and how to help stay cancer-free, visit www.us.femara.com or contact the Novartis toll-free number 1-866-44FEMARA. I'm Matt Kelly.
ANCHOR TAG: Side effects commonly reported with Femara are generally mild to moderate. In the extended adjuvant setting, those seen more often with Femara than with placebo are hot flashes (50% to 43%) arthralgia/arthritis (29% vs. 23%) and myalgia (7% vs. 5%). In a clinical trial, osteoporosis was reported more frequently with Femara than with placebo (7% vs. 6%). During treatment, both arms of the trial showed expected modest decreases in bone mineral density in the hip and spine.
Femara may cause fetal harm when administered to pregnant women. You should not take Femara if you are allergic to Femara or any of its ingredients.
___________________________________________
Produced for Novartis Pharmaceuticals Corporation
November 2004 (Newstream) --
ANCHOR LEAD: A woman's chance of remaining cancer-free following successful treatment for five years with tamoxifen for early breast cancer just got better, thanks to the approval of a new therapy for postmenopausal women. Matt Kelly has more. (:60)
SCRIPT: Healthcare Now, I'm Matt Kelly. Pharmaceutical giant Novartis has just announced a major milestone in the treatment of breast cancer. The drug manufacturer just received FDA approval for Femara in the extended adjuvant setting, making it the first and only post-tamoxifen treatment for postmenopausal women diagnosed with early breast cancer. Dr. Paul Goss, Professor Harvard Medical School.
CUT: (Goss) "The FDA's approval of Femara in the extended adjuvant setting is great news for breast cancer patients because, for the first time, it offers them a new treatment option to help improve their chances of remaining cancer-free after their standard five years of post-surgery tamoxifen therapy."
SCRIPT: An oral once-a-day therapy, Femara plays an important role in suppressing estrogen production, which can cause certain breast cancer cells to grow. To find out more about treatments for breast cancer and how to help stay cancer-free, visit www.us.femara.com or contact the Novartis toll-free number 1-866-44FEMARA. I'm Matt Kelly.
ANCHOR TAG: Side effects commonly reported with Femara are generally mild to moderate. In the extended adjuvant setting, those seen more often with Femara than with placebo are hot flashes (50% to 43%) arthralgia/arthritis (29% vs. 23%) and myalgia (7% vs. 5%). In a clinical trial, osteoporosis was reported more frequently with Femara than with placebo (7% vs. 6%). During treatment, both arms of the trial showed expected modest decreases in bone mineral density in the hip and spine.
Femara may cause fetal harm when administered to pregnant women. You should not take Femara if you are allergic to Femara or any of its ingredients.
___________________________________________
Produced for Novartis Pharmaceuticals Corporation
